Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

Forward-Looking Statements Statements included in this press release and Cadence's conference call that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: Cadence's plan to submit a supplemental new drug application to the FDA for OFIRMEV in flexible plastic bags in the second half of 2013; the company's belief that it will be able to meet its customers' increasing requirements for OFIRMEV; and the company's guidance regarding net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and its ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current intellectual property litigation with the parties that have submitted abbreviated new drug ap
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... the Institute for Molecular Medicine Finland (FIMM), University ... a novel "man and machine" decision support system ... was described in PLOS One scientific ... on computer vision algorithms similar to those used ... only the diagnostically most relevant areas. Tablet computers ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 2014 The College of New Rochelle ... in the Mid-Hudson Region to be designated as a ... applications from qualified “high-technology” businesses that align with the ... to have been selected for the START-UP NY program ... to stimulate economic development in New York by growing ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Sequence Analysis Problem -, - Exhibit to Spotlight ... MISSION VIEJO, Calif., Sept. 26 Supporting ... genomic search,technology, SLIM Search, Inc. announces it is ... Next Generation,Sequencing Conference. The conference will review new ...
... Phil Coggins to Continue as President and CSO, ... Osprey,Pharmaceuticals, Ltd., a privately held biotechnology company developing,first-in-class ... today the appointment of Jack M. Anthony to ... the position of,CEO will continue as President and ...
... September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ... September 24, 2007, the Company received a NASDAQ ... with the minimum,$10 million shareholders, equity requirement for ... forth in Marketplace Rule 4450(a)(3), and that,its ADRs ...
Cached Biology Technology:SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 2SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 3SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market 4Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:8/21/2014)... geologist Juliane Mller the Fram Strait is a key region ... this passage between Greenland and Svalbard warm Atlantic water flows ... west side cold Arctic water masses and sea ice push ... A considerable portion of the Atlantic water cools here on ... The circulation of the water caused in this manner drives ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
(Date:8/21/2014)... in severe abdominal pain, vomiting and systemic inflammation. Every ... with the disease resulting in 1000 deaths. There is ... fluid and nutritional support. , Dr Jason Bruce, ... research, said "The major causes of pancreatitis include bile ... combined with a high fat diet. In fact, the ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2
... Spanish . Making DNA sequences being passed through ... point that they take on the form of diminutive spaghetti. This ... of the lines of research in which CIC microGUNE is working, ... are shortly to apply for a patent. The technique basically consists ...
... New York / Heidelberg, 6 April 2011 The ... pads of many insects, lizards and spiders give them the ... James Bullock and Walter Federle from the University of Cambridge ... away these adhesive hairs from surfaces are what allows beetles ...
... used to rehabilitate the arms and hands of people who ... the University of Southampton. In a paper to be ... and Technology (IET) Assisted Living Conference, Dr Geoff Merrett, a ... and evaluation of three technologies which could help people who ...
Cached Biology News:DNA stretching -- A new technique being carried out at CIC microGUNE to detect illnesses 2Nature helps to solve a sticky problem 2Scientists develop new technology for stroke rehabilitation 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Plus is a chemiluminescent signal enhancing ... to boost the signal obtained with ... kits. ChemiLucent™ Plus is derived from ... conjugated complex- or chemiluminescent substrate enhancers, ...
... Multi-Disciplinary Team The Schleicher & ... stand-alone work center dedicated to custom ... The facilitys experienced project teams, comprised ... Marketing professionals, work closely with collaborators ...
... microRNA (miRNA) expression profiling service using Paraflo ... highly sensitive and specific direct detection of ... mature miRNA of all species available in ... database (Release 8.2). Our service is comprehensive ...
Biology Products: